FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Your NCI: Top Priorities from AACR 2026 May 4, 2026 Preparación para el fin de la emergencia de salud pública (PHE)... April 3, 2023 Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) November 19, 2020 Load more HOT NEWS 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel... ESMO Calls for Cancer Care Integration in EU Global Health Resilience... Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients
